Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

But it is an oral version of the GLP-1 analogue that holds the greatest promise for patients with diabetes - and for the company's revenues. Phase 3 trials of injectable semaglutide have shown it ...

Here’s a quick biology lesson on semaglutide’s mechanisms of action (stick with us — we ... the manufacturer of the diabetes and weight loss drugs Mounjaro® and Zepbound®.

The SOUL trial showed that oral semaglutide was safe in patients with type 2 diabetes and atherosclerotic cardiovascular ...

Scientists may have identified a way to naturally regulate blood sugar levels and sugar cravings in a similar fashion to ...

Semaglutide effectively treats liver disease in two thirds of patients, new research has found. Results from the ESSENCE phase 3 clinical trial published today in the New England Journal of Medicine ...

More information: Alan Y. Hsu et al, Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes, JAMA Ophthalmology (2025). DOI: 10.1001/jamaophthalmol.2025.0349 ...

Tirzepatide linked to more GI issues than semaglutide in new study on weight-loss drugs without diabetes. Read more!

Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes ... from taking action against its members for making copies of semaglutide.

Although the exact mechanism of action has not been revealed ... and other hypoglycemic agents for diabetes treatment. Semaglutide is an ingredient in diabetes and obesity treatments developed ...

Semaglutide use associated with increased risk for NAION at the two-, three-, and four-year time point from the index date. (HealthDay News) — For patients with diabetes, semaglutide use is ...